Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relapsing Forms of Multiple Sclerosis Clear all
Completed No phase listed Observational

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab

NCT01070836
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
35,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
473
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucaloosa, Alabama + 386 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Sep 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis

NCT01158183
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BAY86-5046_Interferon-beta-1b
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
27
States / cities
Many Locations, Alabama • Many Locations, California • Many Locations, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

NCT03277261
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab, Teriflunomide, Oral Placebo, IV Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Carlsbad, California • Long Beach, California • Pasadena, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 22, 2026, 4:37 AM EDT
Terminated No phase listed Observational

Study of Diroximel Fumarate in the Real-World Setting

NCT04746976
View directory record Official record
Conditions
Relapsing Forms of MS
Interventions
Diroximel Fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
West Hollywood, California • Washington D.C., District of Columbia • Louisville, Kentucky + 15 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

NCT06395909
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

NCT01903291
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
62
States / cities
Birmingham, Alabama • Tuscon, Arizona • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 2 Interventional

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

NCT00109161
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
Drug
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Sep 22, 2026, 4:37 AM EDT
Active, not recruiting Phase 4 Interventional

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

NCT06444113
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ofatunumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Winfield, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

NCT00595920
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Interventions
Tovaxin
Biological
Lead sponsor
Opexa Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Results available

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

NCT01216072
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod, Standard MS DMTs
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
142
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Sep 22, 2026, 4:37 AM EDT
Recruiting Phase 1 Interventional

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

NCT06138132
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions
KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
Biological · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

Tecfidera Lymphocyte Chart Review

NCT02519413
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Homewood, Alabama • Newport Beach, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Results available

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

NCT03135249
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Alemtuzumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Rebif New Formulation (RNF) Quality of Life (QOL) Study

NCT00472797
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Rebif New Formulation Non Titrated, Rebif New Formulation Titrated
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 22, 2026, 4:37 AM EDT
Terminated Phase 4 Interventional Results available

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

NCT02117050
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

NCT01201356
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
34
States / cities
Cullman, Alabama • Oceanside, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

NCT00464074
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
30
States / cities
Phoenix, Arizona • Fresno, California • Atlanta, Georgia + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

NCT03623243
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis
Interventions
Siponimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
54
States / cities
Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 22, 2026, 4:37 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

NCT00914758
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Washington Neuropsychology Research Group
Other
Eligibility
25 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
7
States / cities
Berkely, California • Lexington, Kentucky • Springfield, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

NCT01585766
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Forms
Interventions
MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, PLACEBO-IV-SC, MEDI-551 100 MG-IV, MEDI-551 300 MG-SC, MEDI-551 600 MG-IV
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • Long Beach, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 22, 2026, 4:37 AM EDT
Terminated Phase 1 Interventional

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

NCT01144351
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ELND002, Placebo
Drug
Lead sponsor
Elan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
17
States / cities
Berkeley, California • Fresno, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

NCT05028634
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine
Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

NCT01864148
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033, Placebo, Avonex
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Cullman, Alabama • Phoenix, Arizona • Raleigh, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Results available

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

NCT03784898
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood draw for future biomarker analysis
Other
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 22, 2026, 4:37 AM EDT